WuXi STA
One Stop Solution for Pharmaceutical Development and Manufacturing
About
WuXi STA describes itself as "an integral part of WuXi AppTec, an industry-leading pharmaceutical development and manufacturing capability and technology platform serving the life sciences industry with operations across Asia, North America and Europe," offering CDMO solutions for integrated CMC from preclinical to commercial. Scope covers drug substance (small molecule API process R&D and manufacturing, high-potency API), drug product (oral and parenteral), analytical services and regulatory dossier preparation, plus oligonucleotides and peptides through its WuXi TIDES business. Its facilities page lists nine sites: six in Asia, two in North America (Middletown, Delaware and San Diego, California) and one in Europe (Couvet, Neuchatel, Switzerland).
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing iCounts how many of the 22 core manufacturing capabilities this profile lists (7 drug-substance, 6 drug-product, 5 advanced-therapy, 4 specialized) - each adds 3.6 points, capped at 78 - plus 2.4 points per therapeutic area covered, capped at 22. Levels: 80+ Full-spectrum CDMO | 60-79 Broad capability | 40-59 Established | below 40 Focused. Whether this dimension matters for you depends on your specific project.
40Established
Advanced therapy iCounts the 5 advanced-therapy capabilities (cell therapy, gene therapy, viral vectors, CAR-T, exosomes) at 11 points each, capped at 50, then adds bonuses for related depth: biologics drug substance 14, mRNA 12, viral vectors 10, CAR-T 8, plasmid DNA 6. Levels: 80+ ATMP leader | 60-79 Advanced | 40-59 Emerging | below 40 Limited. Whether this dimension matters for you depends on your specific project.
12Limited
Fill-finish iCounts the 6 fill-finish capabilities (vial, syringe, cartridge, blow-fill-seal, isolator, RABS) at 8 points each, capped at 42, plus 16 for sterile injectables, 12 for isolator filling, 8 for RABS. Suite count adds up to 22 more (22 at 20+ suites, 16 at 10+, 10 at 5+, 5 for any). Levels: 80+ High-capacity sterile | 60-79 Strong | 40-59 Capable | below 40 Developing. Whether this dimension matters for you depends on your specific project.
68Strong
Quality iBlends GMP certification (16), Annex 1 compliance (14) and a data-integrity program (10) with reported metrics: inspection pass rate up to 24, quality score up to 18, plus bonuses for low CAPA counts (up to 8) and few audit findings last year (up to 10 for zero). Shows Not reported (score 0) when no GMP flag, pass rate, quality score or data-integrity program is on file. Levels: 80+ Exceptional | 60-79 Strong | 40-59 Solid | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Not reported
Regulatory iCounts entries in three profile lists: regulatory history (6 points each, capped at 46), inspection authorities (7 points each, capped at 30) and geographic coverage (6 points each, capped at 24). More filings, more agencies and wider geography all raise the score. Levels: 80+ Global reach | 60-79 Multi-region | 40-59 Regional | below 40 Limited. Whether this dimension matters for you depends on your specific project.
24Limited
Capacity iTiers four scale metrics: facilities (up to 28 points at 30+), manufacturing suites (up to 24 at 40+), annual unit capacity (up to 26 at 1,000,000+) and employee count (up to 22 at 10,000+). Each metric earns partial points at lower tiers, so any reported scale contributes. Levels: 80+ Global scale | 60-79 Large | 40-59 Mid-size | below 40 Boutique. Whether this dimension matters for you depends on your specific project.
15Boutique
Capabilities
Sterile fill-finishmRNAPeptidesHPAPIOral solidsVial fillingSyringe fillingIsolatorBlow-fill-sealProcess devClinical mfgCommercial mfg
Technology platforms
Flow chemistrybiocatalysiscrystallization and particle engineeringprep-HPLC/SFC/SMB; spray-dried dispersionhot-melt extrusionlipid formulation and nano-suspension for oral bioavailability; lipid nanoparticle (LNP) GMP manufacturing platform; WuXi TIDES oligonucleotide and peptide platform. Parenteral manufacturing (Wuxi CityChina; expanding to CouvetSwitzerland and MiddletownDelaware) runs 5 production lines with fully enclosed isolation systems and automated fillingfilling into vialsprefilled syringescartridges and LDPE ampouleswith solutionemulsion/suspensionlyophilized powderin-situ hydrogel and advanced (liposome/LNP/nanoparticle) formslyophilizers up to 20 m2one blow-fill-seal line for eye drops and inhalantsand a dedicated high-potency injectable line (OEL 10 ng/m3).
Therapeutic areas
OncologyMetabolic diseaseRare disease
Live record · illustrative seed data · scores deterministic, rules-based — not AI.